Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

share with twitter share with LinkedIn share with facebook
share via e-mail
02/19/2020 | 08:46am EDT

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi.

The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

'Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease,' said BARDA Director Rick A. Bright, Ph.D. 'Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks.'

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing manufacturing capacity for recombinant influenza vaccine in the United States, in accordance with a presidential executive order to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government launched a single point-of-entry website for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.

Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA).

BARDA also opened an easy broad agency announcement, an EZ-BAA, specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

About HHS, ASPR, and BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures - vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVe brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation's health security.


Tel: 202-205-8117

Email: asprmedia@hhs.gov

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
06:37aREGENERON PHARMACEUTICALS : First patient outside U.S. treated in global Kevzara..
06:36aSANOFI : - First patient outside U.S. treated in global Kevzara clinical trial p..
03/30Postponement of Annual General Meeting of Sanofi - Aventis Pakistan Limited
03/30SANOFI : receives positive CHMP opinion for Sarclisa for the treatment of relaps..
03/30SANOFI : Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccin..
03/30REGENERON PHARMACEUTICALS : Sanofi, Regeneron expand testing of potential corona..
03/30SANOFI : First patient outside U.S. treated in global Kevzara® (sarilumab) clini..
03/27TRANSLATE BIO : Shares Gain After FDA Grants Rare Pediatric Disease Designation
03/27SANOFI : Translate Bio to Develop Covid-19 Vaccine Candidate
03/27SANOFI : receives positive CHMP opinion for Sarclisa® (isatuximab) for the treat..
More news
Financials (EUR)
Sales 2019 36 409 M
EBIT 2019 9 632 M
Net income 2019 3 910 M
Debt 2019 15 066 M
Yield 2019 3,92%
P/E ratio 2019 26,6x
P/E ratio 2020 18,9x
EV / Sales2019 3,17x
EV / Sales2020 3,05x
Capitalization 100 B
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 100,18  €
Last Close Price 80,14  €
Spread / Highest target 42,3%
Spread / Average Target 25,0%
Spread / Lowest Target -0,17%
EPS Revisions
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Chief Medical & Digital Officer
John C. Reed EVP & Global Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-10.17%111 121
JOHNSON & JOHNSON-15.57%350 661
ROCHE HOLDING AG-5.53%273 496
MERCK & CO., INC-15.39%195 166
NOVARTIS-17.30%183 669
PFIZER, INC.-16.62%181 241